PBYI
Puma Biotechnology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
PBYI Profile
Puma Biotechnology, Inc.
A biopharmaceutical company that develops drug candidates for the treatment of cancer
Biological Technology
04/27/2007
01/03/2017
NASDAQ Stock Exchange
172
12-31
Common stock
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024
--
Puma Biotechnology, Inc., a Delaware corporation, was founded on April 27, 2007. The company is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve patient outcomes. The company is currently commercializing NERLYNX, an oral version of nelatinib for the treatment of HER2-positive breast cancer.